Basic Avana Information

• INN (International Nonproprietary Name): Avanafil.
• Brand Names Available In Canada (English): Stendra — foil blisters, tablets in 50 mg, 100 mg, 200 mg strengths.
• ATC Code: G04BE11 (phosphodiesterase type‑5 inhibitor for genito‑urinary system and sex hormones).
• Forms & Dosages: Oral tablets only; available in 50 mg, 100 mg, 200 mg strengths; no topical or parenteral forms specified.
• Manufacturers In Canada (English): Stendra marketed in Canada; global suppliers include Vivus Inc. (Stendra) and Menarini Group in other regions.
• Registration Status In Canada (English): Approved by Health Canada as Stendra for the treatment of erectile dysfunction.
• OTC / Rx Classification: Prescription only (Rx) in Canada.
• Standard Dosages & Use Cases: Typical starting dose is 100 mg taken about 15 minutes before sexual activity; adjustable to 50 mg (special populations) or 200 mg (if lower doses ineffective); maximum frequency once daily.
• Dosage Modifications: Children — not indicated; elderly — no initial adjustment but use caution; renal impairment — mild/moderate no change, severe use caution; hepatic impairment — lower dose in mild/moderate, avoid in severe impairment.
• Typical Treatment Duration & Regimen: On‑demand use only; taken before anticipated sexual activity; not indicated for daily maintenance dosing.
• Missed Dose & Overdose Instructions: Missed dose not applicable for on‑demand use; in case of overdose seek immediate medical attention for symptoms such as severe hypotension or prolonged erection (priapism).
• Storage & Transport Guidelines: Store at room temperature 20–25°C (68–77°F); excursions 15–30°C permitted; keep in original light‑protected packaging; do not refrigerate or freeze.
• Absolute Contraindications: Concurrent nitrates, use with guanylate cyclase stimulators (e.g., riociguat), known hypersensitivity to avanafil or excipients, severe cardiovascular instability (unstable angina, recent MI/stroke), severe hepatic impairment.
• Relative Contraindications: Anatomical penile deformation (Peyronie’s), predisposition to priapism (sickle cell, leukemia, multiple myeloma), severe renal impairment, recent cardiac events, active arrhythmias, poorly controlled blood pressure, retinitis pigmentosa.
• Common Side Effects: Mild — headache, flushing, nasal congestion, back pain, dizziness; Moderate — hypotension, blurred vision, palpitations, nausea.
• Major Competitors (PDE5 Inhibitors): Sildenafil (Viagra/generics), tadalafil (Cialis), vardenafil (Levitra/Staxyn).
• Clinical Use Cases: First‑line for erectile dysfunction when rapid onset is desired; select when lower visual side effects are preferred due to lower PDE6 cross‑reactivity.
• Other Information: No widely available generics in Canada as of current data; not indicated for women or children; does not affect fertility or provide protection against sexually transmitted infections.

Latest Research Highlights (Canada & International) — Evidence Summary, 2022–2025

Patients ask: “How quickly will this work and is it well tolerated?”

Clinical evidence and post‑marketing surveillance across markets emphasise avanafil’s rapid onset and favourable tolerability compared with some other PDE5 inhibitors.

Available regulatory and product data report that the 100 mg dose can act in about 15 minutes and the 50 mg dose may show effects by about 30 minutes for many users.

Reported adverse events align with the PDE5 class and include headache and flushing as the most common reactions, with rare but serious events such as hypotension and priapism noted.

International randomized controlled trials confirm meaningful erection hardness and sexual function improvements within short onset windows, with generally comparable overall efficacy to sildenafil and vardenafil in measured domains.

Safety signals include lower reported visual disturbances with avanafil than with some comparators, consistent with its lower PDE6 cross‑reactivity in pharmacology data.

Canadian post‑marketing summaries and pharmacovigilance reports mirror expected class effects and list rare serious events; head‑to‑head long‑term Canadian cohort data remain limited.

• Top Evidence Gaps:
  • Longer head‑to‑head comparative trials in Canadian populations.
  • Real‑world data with adequate Indigenous and rural representation.
  • Long‑term tolerability studies in complex multimorbidity (cardiac comorbidity) cohorts.

Data Highlight — Rapid Onset Metrics: 100 mg ≈ 15 minutes; 50 mg ≈ 30 minutes for many participants.

Clinical Effectiveness In Canada — Health Canada & Real‑World Use

People often want to know: “Does it work as well as the brands I’ve heard of?”

Health Canada authorizes avanafil as Stendra for on‑demand treatment of erectile dysfunction with approved doses of 50 mg, 100 mg and 200 mg.

Clinical effectiveness focuses on achieving an erection sufficient for intercourse and improvements in validated domains such as erection hardness and the International Index of Erectile Function (IIEF).

Canadian primary‑care audits and international trial summaries report similar effectiveness to other PDE5 inhibitors when doses are selected and titrated appropriately.

When counselling, pharmacists check the product’s Drug Identification Number (DIN) on labels and confirm coverage routes for patients seeking reimbursement or claims.

• Common Clinical Endpoints (definition list):
  • IIEF: International Index of Erectile Function assessing multiple sexual function domains.
  • EH Score: Erection Hardness score indicating functional erection firmness.
  • Patient Satisfaction: Subjective satisfaction measures and continuation rates in practice.

Indications & Expanded Uses — Approved Versus Off‑Label Practice In Canada

Many patients ask: “What is this approved for, and is there anything else doctors try?”

Approved Indication In Canada: on‑demand treatment of erectile dysfunction in men with Stendra (avanafil).

• Approved
  • On‑demand treatment of erectile dysfunction (males) — doses 50/100/200 mg.
• Not Approved / Investigational
  • Use in women or children — not indicated.
  • Pulmonary hypertension — investigational only and not supported by robust data or approval.
  • Other specialist investigational uses such as procedural facilitation of nocturnal penile tumescence assessment — limited evidence.

Clinician guidance in Canada is to refer complex cases (neurogenic ED, post‑prostatectomy management) to urology or sexual medicine specialists rather than routine off‑label prescribing.

Patient‑centred considerations include culturally safe, bilingual counselling for Indigenous and francophone patients and privacy‑aware approaches for residents of small towns.

Health Canada’s product monograph and the DIN on the product label remain the authoritative references for approved uses at the point of care.

Composition & Brand Landscape — Ingredients, Brands, Generics, Packaging

Common practical question: “Which brands and doses will I see on the shelf?”

Active Ingredient: avanafil (INN).

In Canada the marketed brand is Stendra with film‑coated tablets in 50 mg, 100 mg and 200 mg strengths packaged in foil blisters.

• Generic Availability: No widely available generics specified in Canada as of current data.

Pharmacy practical note: always verify bilingual labelling, the DIN and expiry date on blister packaging before dispensing.

• Pharmacy Checklist:
  • Confirm DIN, lot number and expiry.
  • Ensure bilingual (EN/FR) patient information is available where required.
  • Advise on storage: keep at 20–25°C in original packaging.

Contraindications & Special Precautions — Health Canada Advisories And High‑Risk Groups

Patients often worry: “Is this safe with my heart pills?”

Absolute contraindications include concurrent nitrates, coadministration with guanylate cyclase stimulators such as riociguat, severe cardiovascular instability, known hypersensitivity to avanafil or excipients, and severe hepatic impairment.

Relative cautions include recent myocardial infarction or stroke, uncontrolled arrhythmias, severe renal disease, retinitis pigmentosa, and conditions that predispose to priapism.

• Quick Reference: Absolute Vs Relative Contraindications
  • Absolute: Nitrates, riociguat, severe hepatic impairment, known hypersensitivity, unstable cardiac disease.
  • Relative: Significant renal impairment, recent cardiac events, retinal disorders, high priapism risk.

Canadian pharmacists should flag nitrate prescriptions and recent cardiac events in patient records and coordinate with prescribers, particularly for older adults on multiple cardiovascular medicines.

Emergency signs to act on include chest pain, syncope, severe dizziness or an erection lasting longer than four hours (priapism), in which case immediate medical attention is required.

Dosage Guidelines — Standard Canadian Dosing And Adjustments

Typical patient question: “How do I start and what should I expect?”

Standard On‑Demand Dosing: start at 100 mg taken about 15 minutes before sexual activity.

Adjust to 50 mg when there are interaction risks or tolerability concerns and consider 200 mg only if lower doses are ineffective and tolerated.

Renal and hepatic guidance: elderly patients need no initial adjustment but use clinical judgement; mild to moderate renal impairment usually requires no change, while severe renal or severe hepatic impairment warrants caution or avoidance.

Practical patient tips: try the first dose in a comfortable, private setting and record the timing and any side effects to report at follow‑up consultations.

Interactions Overview — Drugs, Food, Alcohol And Canadian Lifestyle Considerations

A frequent concern is: “Will my other medicines or dinner affect it?”

Major drug interactions: nitrates remain an absolute contraindication due to risk of life‑threatening hypotension.

Potent CYP3A4 inhibitors (for example ritonavir, ketoconazole) can increase avanafil exposure and may require dose adjustment or avoidance.

Grapefruit juice may increase exposure; high‑fat meals can delay absorption and blunt the rapid onset advantage.

• High‑Priority Interaction List:
  • Do not combine with nitrates.
  • Avoid coadministration with riociguat and other guanylate cyclase stimulators.
  • Use caution with potent CYP3A4 inhibitors; consider lower starting dose.

Alcohol: moderate consumption is usually acceptable but heavy drinking raises the risk of hypotension and can reduce sexual performance and drug effectiveness.

Canadian pharmacists should use provincial e‑health records where available to screen for interacting prescriptions and document counselling in the patient file.

Cultural Perceptions & Patient Habits In Canada — Access, Stigma, And Forums

Many men worry about cost, privacy and stigma when seeking treatment for ED.

Universal health coverage in Canada does not typically extend to routine ED medications, which creates cost barriers and influences treatment decisions.

Online communities and patient forums commonly discuss spontaneity, side effects and affordability, and francophone and Indigenous groups often request bilingual, culturally safe information.

• Common Patient Concerns:
  • Cost and lack of public coverage.
  • Confidentiality in small communities.
  • Need for bilingual and culturally safe counselling.

Pharmacy chains with private consultation rooms can reduce stigma and protect privacy for patients seeking treatment.

Availability & Pricing Patterns — Pharmacies, Online, Cross‑Border Notes

Typical question: “Where can I buy this and how much will it cost?”

Availability: Stendra (avanafil) is sold in Canadian pharmacies in 50 mg, 100 mg and 200 mg strengths.

Typical retail sources include major chains and licensed online Canadian pharmacies; always verify the DIN and manufacturer information at purchase.

Pricing: routine ED medications are often paid out‑of‑pocket; private insurance or manufacturer programs may reduce costs for some patients.

Cross‑border buying is discussed by some Canadians as a cost‑saving option, but import rules, safety concerns and authenticity risks should be considered before ordering internationally.

Important safety recommendation: buy only from licensed Canadian pharmacies and verify DIN and expiry on the packaging before accepting delivery.

Purchase Context: In our online pharmacy, avana is available without a prescription, with discreet delivery to Canada (English) in 5‑14 days.

Comparable Medicines & Patient Preferences — How Avanafil Stacks Up In Canada

Patients commonly ask: “Should I pick avanafil, sildenafil, tadalafil or vardenafil?”

• Pros and Cons Summary:
  • Avanafil: fast onset and lower reported visual effects; may cost more than generic sildenafil.
  • Sildenafil: well established, generics widely available and often cheaper.
  • Tadalafil: best option when a long duration or daily therapy is desired.

Matching the right PDE5 inhibitor requires attention to comorbidities, drug interactions and patient lifestyle preferences.

FAQ — Common Canadian Patient Questions

Q1: Is Stendra covered by provincial drug plans?

A1: Routine ED medications are usually not listed on standard public formularies such as the Ontario Drug Benefit, BC PharmaCare or RAMQ; check private insurance or exceptional access policies for coverage options.

Q2: How soon before sex should I take it?

A2: Standard guidance is 100 mg about 15 minutes before intercourse; 50 mg may require around 30 minutes; do not take more than once in 24 hours.

Q3: Can I take it with alcohol?

A3: Moderate alcohol is generally acceptable but heavy drinking increases hypotension risk and can reduce effectiveness.

Q4: What if I’m on heart medication?

A4: Do not take avanafil with nitrates; discuss all cardiac medications with a prescriber or pharmacist to screen for interactions.

Q5: Where can I buy safely?

A5: Purchase from licensed Canadian pharmacies and verify the DIN and manufacturer on the product packaging before use.

• Emergency Signs To Watch For:
  • Priapism (erection >4 hours), chest pain, sudden dizziness or fainting — seek immediate medical care.

Patient Note: ask the pharmacist for bilingual (EN/FR) leaflets and a private counselling room at major chains like Shoppers Drug Mart, Rexall, Jean Coutu or London Drugs.

Guidelines For Proper Use — Pharmacist And Provincial Tips

Practical checklist question: “What should my pharmacist do before handing this out?”

Pharmacist Action Items: confirm Health Canada approval and the DIN; review the full medication list for nitrates and CYP3A4 inhibitors; counsel on dosing and timing; document counselling in the pharmacy record; and provide bilingual materials if needed.

Provincial Tips: follow provincial privacy and prescribing rules and use provincial e‑health records where available to confirm concomitant medications.

• Screening Checklist:
  • Confirm absence of nitrates or riociguat.
  • Assess cardiac history and recent events.
  • Recommend starting dose and follow‑up plan.
  • Provide emergency plan for priapism or severe adverse reactions.

For remote communities: offer telehealth follow‑ups, mail‑order options from licensed pharmacies, and culturally safe counselling for Indigenous and francophone patients.

Refer to urology or cardiology when users have complex comorbidities, recurrent priapism risk, or poor response to appropriately titrated dosing.

Delivery Across Canada (English)